NovoCure (NVCR) Cash from Investing Activities Growth (3y) (2017 - 2026)
NovoCure (NVCR) Cash from Investing Activities Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.11 Bn | 194.51 Bn | 7.27 Bn | 17.83% |
| 2 | Stryker | 129.85 Bn | 126.37 Bn | 4.50 Bn | -6.23% |
| 3 | Medtronic | 119.93 Bn | 110.71 Bn | 6.41 Bn | -24.52% |
| 4 | Boston Scientific | 74.18 Bn | 73.64 Bn | 3.85 Bn | -32.54% |
| 5 | Edwards Lifesciences | 52.54 Bn | 48.29 Bn | 1.35 Bn | -68.12% |
| 6 | Dexcom | 34.76 Bn | 32.81 Bn | 830.00 Mn | 37.39% |
| 7 | GE HealthCare Technologies | 34.25 Bn | 32.14 Bn | 2.18 Bn | -11.04% |
| 8 | Koninklijke Philips | 26.45 Bn | 23.13 Bn | 4.55 Bn | 19.58% |
| 9 | Steris | 23.29 Bn | 22.80 Bn | 684.20 Mn | -17.67% |
| 10 | NovoCure | 2.06 Bn | 1.62 Bn | 142.48 Mn | 22.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.86% |
| Mar 31, 2026 | -54.51% |
| Dec 31, 2025 | 66.63% |
| Sep 30, 2025 | 35.28% |
| Jun 30, 2025 | -38.64% |
| Mar 31, 2025 | 28.10% |
| Dec 31, 2024 | 64.56% |
| Sep 30, 2024 | -67.71% |
| Jun 30, 2024 | -422.96% |
| Mar 31, 2024 | 65.65% |
| Dec 31, 2023 | 29.28% |
| Sep 30, 2023 | -51.06% |
| Jun 30, 2023 | -61.24% |
| Mar 31, 2023 | 205.25% |
| Dec 31, 2022 | -39.91% |
| Sep 30, 2022 | -310.37% |
| Jun 30, 2022 | 349.97% |
| Mar 31, 2022 | -160.14% |
| Dec 31, 2021 | -553.42% |
| Sep 30, 2021 | 571.80% |